International Journal of Cardiology
Volume 135, Issue 3 , Pages 331-337 , 10 July 2009

Influence of pre-hypertension on all-cause and cardiovascular mortality: The Singapore Cardiovascular Cohort Study

  • Jeannette Lee

      Affiliations

    • Community, Occupational and Family Medicine, Yong Loo Lin School of Medicine, National University of Singapore, Singapore
    • Corresponding Author InformationCorresponding author. Community, Occupational and Family Medicine, Yong Loo Lin School of Medicine, MD3, National University of Singapore, 16 Medical Drive, Singapore 117597, Singapore. Tel.: +65 65164964; fax: +65 67791489.
    • ,
  • Derrick Heng

      Affiliations

    • Ministry of Health, Singapore
    • ,
  • Stefan Ma

      Affiliations

    • Ministry of Health, Singapore
    • ,
  • Suok-Kai Chew

      Affiliations

    • Ministry of Health, Singapore
    • ,
  • Kenneth Hughes

      Affiliations

    • Community, Occupational and Family Medicine, Yong Loo Lin School of Medicine, National University of Singapore, Singapore
    • ,
  • E-Shyong Tai

      Affiliations

    • Department of Endocrinology, Singapore General Hospital, Singapore

Received 15 October 2007 ,Revised 16 January 2008 ,Accepted 29 March 2008.

References 

  1. World Health Organization. Cardiovascular disease: prevention and control. Available at http://www.who.int/dietphysicalactivity/publications/facts/cvd/en.
  2. Lawes CM, Vander Hoorn S, Law MR, Elliott P, MacMahon S, Rodgers A. Blood pressure and the global burden of disease 2000. Part II: estimates of attributable burden. J Hypertens. 2006;24:423–430
  3. Chobanian AV, Bakris GL, Black HR, et al. National Heart, Lung, and Blood Institute Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure; National High Blood Pressure Education Program Coordinating Committee The seventh report of the Joint National Committee on prevention, detection, evaluation, and treatment of high blood pressure: the JNC 7 report. Hypertension. 2003;42:1206–1252
  4. Vasan RS, Larson MG, Leip EP, Kannel WB, Levy D. Assessment of frequency of progression to hypertension in non-hypertensive participants in the Framingham Heart Study: a cohort study. Lancet. 2001;358:1682–1686
  5. Lewington S, Clarke R, Qizilbash N, Peto R, Collins R Prospective Studies Collaboration. Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. Lancet. 2002;360:1903–1913
  6. Mancia G, De Backer G, Dominiczak A, et al. ESH -ESC Task Force on the Management of Arterial Hypertension 2007 ESH-ESC Practice Guidelines for the Management of Arterial Hypertension: ESH-ESC Task Force on the Management of Arterial Hypertension. J Hypertens. 2007;25:1751–1762
  7. Williams B, Poulter NR, Brown MJ, et al. British Hypertension Society Guidelines for management of hypertension: report of the fourth working party of the British Hypertension Society, 2004-BHS IV. J Hum Hypertens. 2004;18:139–185
  8. Kannel WB. Fifty years of Framingham Study contributions to understanding hypertension. J Hum Hypertens. 2000;14:83–90
  9. Qureshi AI, Suri MF, Kirmani JF, Divani AA, Mohammad Y. Is prehypertension a risk factor for cardiovascular diseases?. Stroke. 2005;36:1859–1863
  10. Liszka HA, Mainous AG, King DE, Everett CJ, Egan BM. Prehypertension and cardiovascular morbidity. Ann Fam Med. 2005;3:294–299
  11. Zhang Y, Lee ET, Devereux RB, et al. Prehypertension, diabetes, and cardiovascular disease risk in a population-based sample: the Strong Heart Study. Hypertension. 2006;47:410–414
  12. Kshirsagar AV, Carpenter M, Bang H, Wyatt SB, Colindres RE. Blood pressure usually considered normal is associated with an elevated risk of cardiovascular disease. Am J Med. 2006;119:133–141
  13. Mainous AG, Everett CJ, Liszka H, King DE, Egan BM. Prehypertension and mortality in a nationally representative cohort. Am J Cardiol. 2004;94:1496–1500
  14. Takagi S, Saitoh S, Nakano M, et al. Relationship between blood pressure level and mortality rate: an 18-year study conducted in two rural communities in Japan. J Hypertens. 2000;18:139–144
  15. Asia Pacific Cohort Studies Collaboration. Joint effects of systolic blood pressure and serum cholesterol on cardiovascular disease in the Asia Pacific region. Circulation. 2005;112:3384–3390
  16. Heng DM, Lee J, Chew SK, Tan BY, Hughes K, Chia KS. Incidence of ischaemic heart disease and stroke in Chinese, Malays and Indians in Singapore: Singapore Cardiovascular Cohort Study. Ann Acad Med Singapore. 2000;29:231–236
  17. Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem. 1972;18:499–502
  18. Goldstein LB, Adams R, Alberts MJ, et al. American Heart Association; American Stroke Association Stroke Council Primary prevention of ischemic stroke: a guideline from the American Heart Association/American Stroke Association Stroke Council: cosponsored by the Atherosclerotic Peripheral Vascular Disease Interdisciplinary Working Group; Cardiovascular Nursing Council; Clinical Cardiology Council; Nutrition, Physical Activity, and Metabolism Council; and the Quality of Care and Outcomes Research Interdisciplinary Working Group. Circulation. 2006;113:e873–e923
  19. Sacco RL, Adams R, Albers G, et al. American Heart Association/American Stroke Association Council on Stroke; Council on Cardiovascular Radiology and Intervention; American Academy of Neurology Guidelines for prevention of stroke in patients with ischemic stroke or transient ischemic attack: a statement for healthcare professionals from the American Heart Association/American Stroke Association Council on Stroke: co-sponsored by the Council on Cardiovascular Radiology and Intervention: the American Academy of Neurology affirms the value of this guideline. Circulation. 2006;113:e409–e449
  20. Nissen SE, Tuzcu EM, Libby P, et al. CAMELOT Investigators Effect of antihypertensive agents on cardiovascular events in patients with coronary disease and normal blood pressure: the CAMELOT study: a randomized controlled trial. JAMA. 2004;292:2217–2225

☆ Source of funding: This study was supported by an unrestricted educational grant from Pfizer Pte Ltd (Singapore).

☆☆ Conflict(s) of interest/disclosure(s): None. Pfizer had no involvement in the data collection, analysis, interpretation of the data, writing of the manuscript, or decision to submit the paper for publication.

PII: S0167-5273(08)00541-X

doi: 10.1016/j.ijcard.2008.03.067

International Journal of Cardiology
Volume 135, Issue 3 , Pages 331-337 , 10 July 2009

Article Tools